• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    $MDRX
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Technology
    Get the next $CMBM alert in real time by email

    Appoints Jonathan Sacks and Bruce Felt to the Board

    Lou Silverman to Succeed Greg Garrison as Chairman

    Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Governance Committee.

    Mr. Sacks is a Partner at Stonehill Capital Management LLC ("Stonehill"), where he has been for over 20 years, and brings deep financial expertise and strategic insight to the Board. At Stonehill he has led and managed debt and equity investments across many industries including healthcare and software. While at Stonehill, Mr. Sacks has had extensive experience investing in companies undergoing complex transitions such as accounting challenges, delistings, and capital structure changes. Stonehill, through funds it manages on behalf of institutional investors and others, is Veradigm's largest shareholder.

    Mr. Felt has served as Chief Financial Officer (CFO) at several public companies in the technology space, including most recently at Domo (NASDAQ:DOMO), a cloud software company that specializes in business intelligence tools and data visualization. During his nearly nine-year tenure as CFO, Mr. Felt oversaw the scaling of Domo's enterprise cloud business and helped take the company public in 2018. Prior to Domo, he served as CFO at SAP SuccessFactors (NASDAQ:SFSF) and FullTime Software (NASDAQ:FTSW), overseeing the sales of both companies. He currently serves on the board of directors of Cambium Networks (NASDAQ:CMBM), including as Audit Committee Chair. Mr. Felt also previously served as lead independent director and Audit Committee Chair at Evolent Health (NYSE:EVH).

    "Veradigm remains focused on strong governance and strategic oversight as we continue to drive innovation and seek to maximize value for our stockholders," said Mr. Garrison. "On behalf of the entire Board, I am pleased to welcome Jonathan and Bruce, who bring deep leadership, financial stewardship, and technology experience to the Board. Additionally, we are confident that with Bruce's extensive financial and accounting background, he is highly qualified to serve as Audit Committee Chair."

    Mr. Garrison continued "I am very pleased that Lou Silverman has agreed to assume the role of Chairman upon my departure. With Lou's 30 years of leadership experience in health information technology and technology-enabled healthcare services, the Board is confident in his ability to lead the Board as it oversees Veradigm's next phase."

    "It will be an honor to serve as Veradigm's Chairman of the Board as the Company navigates this important time," said Mr. Silverman. "I want to thank Greg for his leadership and vision, and I look forward to working closely with the rest of the Board as we focus on our priorities: remediating our material weaknesses and other internal control deficiencies, becoming current in our financial reporting, executing our growth strategy, and relisting our common stock."

    The appointments of Messrs. Felt and Sacks to the Board satisfy Veradigm's obligations under the February 2025 Cooperation Agreement with Kent Lake PR LLC.

    About Veradigm®

    Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions for the healthcare provider, payer, and biopharma markets. For more information about how Veradigm is fulfilling its mission of Transforming Health, Insightfully, visit www.veradigm.com, or find Veradigm on LinkedIn, Facebook, Twitter, Instagram, and YouTube.

    © 2025 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or company names are the property of their respective holders, all rights reserved.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250318997143/en/

    Investors:

    Jenny Gelinas

    312-506-1237

    [email protected]

    Media:

    Amanda Cohen

    412-919-2417

    [email protected]

    Get the next $CMBM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CMBM
    $DOMO
    $EVH
    $MDRX

    CompanyDatePrice TargetRatingAnalyst
    Domo Inc.
    $DOMO
    7/18/2025$19.00Overweight
    Stephens
    Domo Inc.
    $DOMO
    3/7/2025$9.00 → $8.00Neutral
    DA Davidson
    Domo Inc.
    $DOMO
    2/11/2025$11.00Overweight
    Cantor Fitzgerald
    Evolent Health Inc
    $EVH
    1/10/2025$15.00Buy
    Needham
    Evolent Health Inc
    $EVH
    12/3/2024$36.00 → $29.00Buy
    BTIG Research
    Evolent Health Inc
    $EVH
    11/8/2024$38.00 → $16.00Overweight → Equal-Weight
    Stephens
    Evolent Health Inc
    $EVH
    10/11/2024$35.00Overweight
    KeyBanc Capital Markets
    Evolent Health Inc
    $EVH
    8/9/2024$28.00 → $33.00Hold → Buy
    Truist
    More analyst ratings

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock

    WASHINGTON, Aug. 18, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions ("Evolent"), today announced that it intends to offer $140.0 million aggregate principal amount of convertible senior notes due 2031, subject to market and other conditions. Evolent also expects to grant the initial purchasers in the proposed offering an option to purchase up to an additional $20.0 million aggregate principal amount of notes. The notes are being offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act").

    8/18/25 4:05:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Domo Releases Second Annual "Data Never Sleeps: AI Edition" Infographic

    The AI-focused Data Never Sleeps report found that global spend on AI every minute rose by over 300% Domo (NASDAQ:DOMO) today unveiled a special second edition of its Data Never Sleeps: AI Edition infographic, which focuses on AI and its growth over the past year. As an extension of Domo's annual Data Never Sleeps (DNS) report, this edition provides a deep dive into the immense amount of AI data generated on the internet every minute and its impact on our everyday lives. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813908636/en/ "Over the past year, we've witnessed AI move from the periphery to the center of how we create

    8/13/25 9:00:00 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Domo Announces Timing of its Second Quarter Fiscal 2026 Earnings Conference Call

    Domo (NASDAQ:DOMO) today announced that results for its second quarter fiscal 2026 (ended July 31, 2025) will be released on Thursday, August 28, 2025, after the close of the market. The company will host a conference call at 3:00 p.m. (MT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. A live dial-in is available at (877) 484-6065 or (201) 689-8846. A live webcast of the event will also be available on the Domo Investor Relations website at www.domo.com/IR. A replay will be available at (877) 660-6853 or (201) 612-7415 with the access ID#13755353 following the completion of the conference call until 11:59p.m. (ET) September 28, 2025. About Domo Dom

    8/11/25 4:05:00 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stephens initiated coverage on Domo with a new price target

    Stephens initiated coverage of Domo with a rating of Overweight and set a new price target of $19.00

    7/18/25 8:14:38 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    DA Davidson resumed coverage on Domo with a new price target

    DA Davidson resumed coverage of Domo with a rating of Neutral and set a new price target of $8.00 from $9.00 previously

    3/7/25 7:23:12 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Cantor Fitzgerald initiated coverage on Domo with a new price target

    Cantor Fitzgerald initiated coverage of Domo with a rating of Overweight and set a new price target of $11.00

    2/11/25 7:04:19 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    SEC Filings

    View All

    SEC Form 8-K filed by Evolent Health Inc

    8-K - Evolent Health, Inc. (0001628908) (Filer)

    8/18/25 4:18:09 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Domo Inc.

    SCHEDULE 13G/A - DOMO, INC. (0001505952) (Subject)

    8/14/25 6:09:40 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc

    SCHEDULE 13G/A - Evolent Health, Inc. (0001628908) (Subject)

    8/14/25 3:07:26 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Founder and CEO James Joshua G bought $165,897 worth of Class B Common Stock (13,025 units at $12.74), increasing direct ownership by 1% to 1,079,972 units (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    6/23/25 9:37:55 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Director Daniel Daniel David Iii bought $772,452 worth of Class B Common Stock (120,000 units at $6.44) (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    4/4/25 9:37:24 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Founder and CEO James Joshua G bought $502,172 worth of Class B Common Stock (77,300 units at $6.50) (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    4/4/25 9:36:07 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Shams Aammaad covered exercise/tax liability with 2,567 shares, decreasing direct ownership by 3% to 72,899 units (SEC Form 4)

    4 - Evolent Health, Inc. (0001628908) (Issuer)

    8/5/25 4:11:35 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Senior VP, Products Vivek Vibhu covered exercise/tax liability with 3,579 units of Ordinary Shares, decreasing direct ownership by 3% to 117,279 units (SEC Form 4)

    4 - Cambium Networks Corp (0001738177) (Issuer)

    7/14/25 4:00:05 PM ET
    $CMBM
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Founder and CEO James Joshua G was granted 550,000 units of Class B Common Stock, increasing direct ownership by 53% to 1,578,213 units (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    7/3/25 4:03:34 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Veradigm Inc.

    SC 13G - Veradigm Inc. (0001124804) (Subject)

    11/14/24 4:05:58 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Veradigm Inc.

    SC 13G/A - Veradigm Inc. (0001124804) (Subject)

    11/14/24 1:11:13 PM ET
    $MDRX
    EDP Services
    Technology

    Amendment: SEC Form SC 13G/A filed by Domo Inc.

    SC 13G/A - DOMO, INC. (0001505952) (Subject)

    11/14/24 12:25:56 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Leadership Updates

    Live Leadership Updates

    View All

    Veradigm Announces Appointment of Two New Independent Directors and Transition of Board Leadership

    Appoints Jonathan Sacks and Bruce Felt to the Board Lou Silverman to Succeed Greg Garrison as Chairman Veradigm Inc. (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today its Board of Directors (the "Board") appointed two new independent directors, Jonathan Sacks and Bruce Felt, to the Board, effective March 19, 2025, and that Lou Silverman will succeed Greg Garrison as Chairman upon his retirement from the Board on that date. In addition, Mr. Felt will become the Chair of the Audit Committee of the Board upon Mr. Garrison's retirement. Further, independent director Vinit Asar has been named Chair of the Nominating and Go

    3/18/25 4:47:00 PM ET
    $CMBM
    $DOMO
    $EVH
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Computer Software: Prepackaged Software
    Other Consumer Services

    Define Ventures Appoints Carolyn Magill as Venture Partner

    The former Aetion and Remedy Partners CEO joins Define to further drive innovation across provider, payer, and pharmaceutical sectors SAN FRANCISCO, March 11, 2025 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Carolyn Magill, former CEO of Aetion, has joined the firm as venture partner. Magill, leveraging her 25 years of invaluable experience scaling companies and fostering innovation within payer, provider, and pharmaceutical organizations, will partner with Define founders to scale their companies and become category-defining companies.

    3/11/25 5:30:00 AM ET
    $EVH
    $HIMS
    $LVGO
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Veradigm Announces Board Expansion and Changes

    Appoints Vinit Asar and Louis Silverman to its Board of Directors Agrees to Add Two Additional Directors Veradigm® (OTC:MDRX) ("Veradigm" or the "Company"), a leading provider of healthcare data and technology solutions, announced today it has entered into a Cooperation Agreement (the "Agreement") with Kent Lake PR LLC ("Kent Lake"). The Agreement aligns with the Board's request for input from shareholders regarding board composition on January 30, 2025, and a desire to conduct an orderly refreshment of the Board following the conclusion of the exploration of strategic alternatives. As part of the Agreement, the Board has appointed two new independent directors, Vinit Asar and Louis Silve

    2/20/25 4:02:00 PM ET
    $MDRX
    $OCX
    $ZIMV
    EDP Services
    Technology
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $CMBM
    $DOMO
    $EVH
    $MDRX
    Financials

    Live finance-specific insights

    View All

    Domo Announces Timing of its Second Quarter Fiscal 2026 Earnings Conference Call

    Domo (NASDAQ:DOMO) today announced that results for its second quarter fiscal 2026 (ended July 31, 2025) will be released on Thursday, August 28, 2025, after the close of the market. The company will host a conference call at 3:00 p.m. (MT) / 5:00 p.m. (ET) to discuss its financial results with the investment community. A live dial-in is available at (877) 484-6065 or (201) 689-8846. A live webcast of the event will also be available on the Domo Investor Relations website at www.domo.com/IR. A replay will be available at (877) 660-6853 or (201) 612-7415 with the access ID#13755353 following the completion of the conference call until 11:59p.m. (ET) September 28, 2025. About Domo Dom

    8/11/25 4:05:00 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Evolent Announces Second Quarter 2025 Results

    WASHINGTON, Aug. 7, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent" or the "Company"), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make health care simpler and more affordable, today announced financial results for the three months ended June 30, 2025. Seth Blackley, Co-Founder and Chief Executive Officer of Evolent stated, "Evolent exceeded our EBITDA targets for the second quarter and raised our profitability outlook for the full year. In addition, we continue to see a rapidly accelerating pipeline for new business and based on this acceleration we would expect to exceed our historical growth rates fo

    8/7/25 4:10:00 PM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary

    Evolent To Release Second Quarter 2025 Financial Results on Thursday, August 7, 2025

    Company to Participate in Upcoming Conferences WASHINGTON, July 14, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH), a company focused on achieving better health outcomes for people with complex conditions, today announced it will release its second quarter 2025 financial results on Thursday, August 7, 2025, after market close, with a conference call to follow at 5 p.m. ET. Shareholders and interested participants may listen to a live broadcast of the conference call found on Evolent's investor relations website, https://ir.evolent.com. Analysts interested in asking questions during the live call should dial 855.940.9467, or 412.317.6034 for international callers, and reference the "Evo

    7/14/25 8:00:00 AM ET
    $EVH
    Other Consumer Services
    Consumer Discretionary